Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. / Heinrich, Niels S; Theilade, Simone; Winther, Signe A; Tofte, Nete; Ahluwalia, Tarunveer S; Jeppesen, Jørgen L; Persson, Frederik; Hansen, Tine W; Goetze, Jens P; Rossing, Peter.

I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2021.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Heinrich, NS, Theilade, S, Winther, SA, Tofte, N, Ahluwalia, TS, Jeppesen, JL, Persson, F, Hansen, TW, Goetze, JP & Rossing, P 2021, 'Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes', Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. https://doi.org/10.1093/ndt/gfaa308

APA

Heinrich, N. S., Theilade, S., Winther, S. A., Tofte, N., Ahluwalia, T. S., Jeppesen, J. L., Persson, F., Hansen, T. W., Goetze, J. P., & Rossing, P. (2021). Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. https://doi.org/10.1093/ndt/gfaa308

Vancouver

Heinrich NS, Theilade S, Winther SA, Tofte N, Ahluwalia TS, Jeppesen JL o.a. Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2021. https://doi.org/10.1093/ndt/gfaa308

Author

Heinrich, Niels S ; Theilade, Simone ; Winther, Signe A ; Tofte, Nete ; Ahluwalia, Tarunveer S ; Jeppesen, Jørgen L ; Persson, Frederik ; Hansen, Tine W ; Goetze, Jens P ; Rossing, Peter. / Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2021.

Bibtex

@article{1baf57eb8e1e4a1a853a6536d81f5a57,
title = "Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes",
abstract = "BACKGROUND: Plasma copeptin is a surrogate of arginine vasopressin (AVP) secretion and is associated with a risk of renal and cardiovascular disease. We investigated associations between copeptin and renal events, cardiovascular events and mortality in type 1 diabetes (T1D).METHODS: We conducted a prospective cohort study on 658 individuals with T1D from Steno Diabetes Center Copenhagen. Plasma copeptin concentrations and conventional risk factors were assessed at baseline. The five endpoints were traced through national registries and electronic laboratory records.RESULTS: Baseline mean age was 55 ± 13 years and estimated glomerular filtration rate (eGFR) was 81 ± 26 mL/min/1.73 m2. The median follow-up was 6.2 years (interquartile range 5.8-6.7); 123 participants reached a combined renal endpoint [decline in eGFR ≥30%, end-stage kidney disease (ESKD) or all-cause mortality], 93 had a decrease in eGFR ≥30%, 21 developed ESKD, 94 experienced a combined cardiovascular endpoint and 58 died from all causes. Higher copeptin was associated with all endpoints in unadjusted Cox regression analyses. Upon adjustment for baseline eGFR, the associations were attenuated and remained significant only for the combined renal endpoint and decrease in eGFR ≥30%. Results were similar upon further adjustment for other risk factors, after which hazard ratios for the two renal endpoints were 2.27 (95% confidence interval 1.08-4.74) and 4.49 (1.77-11.4), respectively, for the highest versus the lowest quartile of copeptin.CONCLUSIONS: Higher copeptin was an independent risk marker for a combined renal endpoint and decline in renal function. AVP may be a marker of renal damage or a factor whose contribution to renal and cardiovascular risk is partially mediated by renal damage.",
author = "Heinrich, {Niels S} and Simone Theilade and Winther, {Signe A} and Nete Tofte and Ahluwalia, {Tarunveer S} and Jeppesen, {J{\o}rgen L} and Frederik Persson and Hansen, {Tine W} and Goetze, {Jens P} and Peter Rossing",
note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.",
year = "2021",
doi = "10.1093/ndt/gfaa308",
language = "English",
journal = "Nephrology, Dialysis, Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",

}

RIS

TY - JOUR

T1 - Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes

AU - Heinrich, Niels S

AU - Theilade, Simone

AU - Winther, Signe A

AU - Tofte, Nete

AU - Ahluwalia, Tarunveer S

AU - Jeppesen, Jørgen L

AU - Persson, Frederik

AU - Hansen, Tine W

AU - Goetze, Jens P

AU - Rossing, Peter

N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

PY - 2021

Y1 - 2021

N2 - BACKGROUND: Plasma copeptin is a surrogate of arginine vasopressin (AVP) secretion and is associated with a risk of renal and cardiovascular disease. We investigated associations between copeptin and renal events, cardiovascular events and mortality in type 1 diabetes (T1D).METHODS: We conducted a prospective cohort study on 658 individuals with T1D from Steno Diabetes Center Copenhagen. Plasma copeptin concentrations and conventional risk factors were assessed at baseline. The five endpoints were traced through national registries and electronic laboratory records.RESULTS: Baseline mean age was 55 ± 13 years and estimated glomerular filtration rate (eGFR) was 81 ± 26 mL/min/1.73 m2. The median follow-up was 6.2 years (interquartile range 5.8-6.7); 123 participants reached a combined renal endpoint [decline in eGFR ≥30%, end-stage kidney disease (ESKD) or all-cause mortality], 93 had a decrease in eGFR ≥30%, 21 developed ESKD, 94 experienced a combined cardiovascular endpoint and 58 died from all causes. Higher copeptin was associated with all endpoints in unadjusted Cox regression analyses. Upon adjustment for baseline eGFR, the associations were attenuated and remained significant only for the combined renal endpoint and decrease in eGFR ≥30%. Results were similar upon further adjustment for other risk factors, after which hazard ratios for the two renal endpoints were 2.27 (95% confidence interval 1.08-4.74) and 4.49 (1.77-11.4), respectively, for the highest versus the lowest quartile of copeptin.CONCLUSIONS: Higher copeptin was an independent risk marker for a combined renal endpoint and decline in renal function. AVP may be a marker of renal damage or a factor whose contribution to renal and cardiovascular risk is partially mediated by renal damage.

AB - BACKGROUND: Plasma copeptin is a surrogate of arginine vasopressin (AVP) secretion and is associated with a risk of renal and cardiovascular disease. We investigated associations between copeptin and renal events, cardiovascular events and mortality in type 1 diabetes (T1D).METHODS: We conducted a prospective cohort study on 658 individuals with T1D from Steno Diabetes Center Copenhagen. Plasma copeptin concentrations and conventional risk factors were assessed at baseline. The five endpoints were traced through national registries and electronic laboratory records.RESULTS: Baseline mean age was 55 ± 13 years and estimated glomerular filtration rate (eGFR) was 81 ± 26 mL/min/1.73 m2. The median follow-up was 6.2 years (interquartile range 5.8-6.7); 123 participants reached a combined renal endpoint [decline in eGFR ≥30%, end-stage kidney disease (ESKD) or all-cause mortality], 93 had a decrease in eGFR ≥30%, 21 developed ESKD, 94 experienced a combined cardiovascular endpoint and 58 died from all causes. Higher copeptin was associated with all endpoints in unadjusted Cox regression analyses. Upon adjustment for baseline eGFR, the associations were attenuated and remained significant only for the combined renal endpoint and decrease in eGFR ≥30%. Results were similar upon further adjustment for other risk factors, after which hazard ratios for the two renal endpoints were 2.27 (95% confidence interval 1.08-4.74) and 4.49 (1.77-11.4), respectively, for the highest versus the lowest quartile of copeptin.CONCLUSIONS: Higher copeptin was an independent risk marker for a combined renal endpoint and decline in renal function. AVP may be a marker of renal damage or a factor whose contribution to renal and cardiovascular risk is partially mediated by renal damage.

U2 - 10.1093/ndt/gfaa308

DO - 10.1093/ndt/gfaa308

M3 - Journal article

C2 - 33367877

JO - Nephrology, Dialysis, Transplantation

JF - Nephrology, Dialysis, Transplantation

SN - 0931-0509

ER -

ID: 257056466